CL2023003331A1 - Anticuerpos anti-tmprs66 y usos de los mismos. - Google Patents

Anticuerpos anti-tmprs66 y usos de los mismos.

Info

Publication number
CL2023003331A1
CL2023003331A1 CL2023003331A CL2023003331A CL2023003331A1 CL 2023003331 A1 CL2023003331 A1 CL 2023003331A1 CL 2023003331 A CL2023003331 A CL 2023003331A CL 2023003331 A CL2023003331 A CL 2023003331A CL 2023003331 A1 CL2023003331 A1 CL 2023003331A1
Authority
CL
Chile
Prior art keywords
antibodies
tmprss6
tmprs66
bind
disorder
Prior art date
Application number
CL2023003331A
Other languages
English (en)
Spanish (es)
Inventor
Chin Harvey
J Hatsell Sarah
Emil Lob Heinrich
J Murphy Andrew
Olson William
Saotome Kei
Zhang Bojie
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2023003331A1 publication Critical patent/CL2023003331A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2023003331A 2021-05-11 2023-11-08 Anticuerpos anti-tmprs66 y usos de los mismos. CL2023003331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163187150P 2021-05-11 2021-05-11

Publications (1)

Publication Number Publication Date
CL2023003331A1 true CL2023003331A1 (es) 2024-06-07

Family

ID=81927373

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003331A CL2023003331A1 (es) 2021-05-11 2023-11-08 Anticuerpos anti-tmprs66 y usos de los mismos.

Country Status (14)

Country Link
US (2) US12448435B2 (enExample)
EP (1) EP4337695A1 (enExample)
JP (1) JP2024517931A (enExample)
KR (1) KR20240005894A (enExample)
CN (1) CN117730099A (enExample)
AU (1) AU2022274888A1 (enExample)
BR (1) BR112023023558A2 (enExample)
CA (1) CA3218455A1 (enExample)
CL (1) CL2023003331A1 (enExample)
CO (1) CO2023016777A2 (enExample)
IL (1) IL308375A (enExample)
MA (1) MA63064B1 (enExample)
MX (1) MX2023013248A (enExample)
WO (1) WO2022240877A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
WO2024211404A2 (en) * 2023-04-04 2024-10-10 Disc Medicine, Inc. Anti-tmprss6 antibodies and uses thereof
WO2025245434A1 (en) * 2024-05-24 2025-11-27 Disc Medicine, Inc. Compositions and methods for treating myelodysplastic syndromes (mds)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA2991637C (en) 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
KR20220107252A (ko) * 2019-11-29 2022-08-02 키맵 리미티드 생리학적 철분 과다에 대한 치료
CN115243762A (zh) * 2020-04-07 2022-10-25 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2024517931A (ja) 2024-04-23
MX2023013248A (es) 2024-01-29
US20220411487A1 (en) 2022-12-29
BR112023023558A2 (pt) 2024-03-12
MA63064A1 (fr) 2024-02-29
IL308375A (en) 2024-01-01
CN117730099A (zh) 2024-03-19
AU2022274888A1 (en) 2023-12-07
US12448435B2 (en) 2025-10-21
CO2023016777A2 (es) 2023-12-11
EP4337695A1 (en) 2024-03-20
MA63064B1 (fr) 2025-02-28
CA3218455A1 (en) 2022-11-17
US20260098084A1 (en) 2026-04-09
KR20240005894A (ko) 2024-01-12
WO2022240877A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
CL2023003331A1 (es) Anticuerpos anti-tmprs66 y usos de los mismos.
CL2021003290A1 (es) Anticuerpos de unión a cd3. (divisional de solicitud 201900643)
CL2024000378A1 (es) Anticuerpos anti-npr1 y usos de los mismos.
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CL2018003563A1 (es) Anticuerpos anti-c5 y usos de los mismos.
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
PE20220708A1 (es) Anticuerpos anti-cd73
MA49727B1 (fr) Anticorps et polypeptides dirigés contre cd127
JOP20190093A1 (ar) أجسام مضادة لـ il-33 واستخداماتها
EA202192606A1 (ru) Антитела к пироглутамат--амилоиду и их применение
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
JOP20220204B1 (ar) الأجسام المضادة لـ cd19 البشرية
EA201892525A1 (ru) Конструкции днк-антител для применения против pseudomonas aeruginosa
CL2025002112A1 (es) Anticuerpo anti-npr1; método de producción; y su uso.
MX2021010061A (es) Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1.
JOP20250298A1 (ar) تركيبات جسم مضاد لإنتيجرين α4β7 وطرق استخدامها
WO2019246176A8 (en) Anti-factor xii/xiia antibodies and uses thereof
BR112023008317A2 (pt) Proteínas de fusão sap fc e métodos de uso
PY2204506A (es) Anticuerpos antiglicoproteína de espiga y su uso terapéutico
MX2022006026A (es) Anticuerpos monoclonales anti-alfa-sinucleina y metodos que utilizan los mismos.
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
EA202191060A1 (ru) Анти-npr1 антитела и их применение
CO2023015999A2 (es) Proteínas de fusión activas renales y métodos de tratamiento que usan las mismas
EA201892069A1 (ru) Способы лечения или профилактики болезни "трансплантат против хозяина"